Triptorelin depot for the treatment of children 2 years and older with central precocious puberty

References

• Styne DM, Grumbach MM. Physiology and disorders of puberty. In: Henry M, Kronenberg HM, Larsen PR, et al., eds. Williams textbook of endocrinology. 13th ed. Philadelphia, PA: Elsevier Saunders; 2016. p. 1074–1218.
   Google Scholar
• Le Moal J, Rigou A, Le Tertre A, et al. Marked geographic patterns in the incidence of idiopathic central precocious puberty: a nationwide study in France. Eur J Endocrinol. 2018;178:33–41.
   PubMed Web of Science ®Google Scholar
• Carel JC, Eugster EA, Rogol A, et al. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics. 2009;123:e752–62.
   PubMed Web of Science ®Google Scholar
• Pienkowski C, Tauber M. Gonadotropin-releasing hormone agonist treatment in sexual precocity. Endocr Dev. 2016;29:2:14–229.
   Google Scholar
• Partsch CJ, Sippell WG. Treatment of central precocious puberty. Best Pract Res Clin Endocrinol Metab. 2002;16:165–189.
   PubMed Web of Science ®Google Scholar
• Bertelloni S, Baroncelli GI. Current pharmacotherapy of central precocious puberty by GnRH analogs: certainties and uncertainties. Expert Opin Pharmacother. 2013;14:1627–1639.
   PubMed Web of Science ®Google Scholar
• Bereket A. A critical appraisal of the effect of gonadotropin-releasing hormone analog treatment on adult height of girls with central precocious puberty. J Clin Res Pediatr Endocrinol. 2017;9(Suppl 2):33–48.
   PubMedGoogle Scholar
• Durand A, Tauber M, Patel B, et al. Meta-analysis of paediatric patients with central precocious puberty treated with intramuscular triptorelin 11.25 mg 3-month prolonged-release formulation. Horm Res Paediatr. 2017;87:224–232.
   PubMed Web of Science ®Google Scholar
• Lahlou N, Carel JC, Chaussain JL, et al. Pharmacokinetics and pharmacodynamics of GnRH agonists: clinical implications in pediatrics. J Pediatr Endocrinol Metab. 2000;13(Suppl. 1):723–737.
   PubMedGoogle Scholar
• Boepple PA, Mansfield MJ, Wierman ME, et al. Use of a potent, long acting agonist of gonadotropin-releasing hormone in the treatment of precocious puberty. Endocr Rev. 1986;7:24–33.
   PubMed Web of Science ®Google Scholar
• Zenaty D, Blumberg J, Liyanage N, et al. A 6-month trial of the efficacy and safety of triptorelin pamoate (11.25 mg) every 3 months in children with precocious puberty: a retrospective comparison with triptorelin acetate. Horm Res Paediatr. 2016;86:188–195.
   PubMed Web of Science ®Google Scholar
• Klein K, Yang J, Aisenberg J, et al. Efficacy and safety of triptorelin 6-month formulation in patients with central precocious puberty. J Pediatr Endocrinol Metab. 2016;29:1241–1248.
   PubMed Web of Science ®Google Scholar
• Pasquino AM, Pucarelli I, Accardo F, et al. Long-term observation of 87 girls with idiopathic central precocious puberty treated with gonadotropin-releasing hormone analogs: impact on adult height, body mass index, bone mineral content, and reproductive function. J Clin Endocrinol Metab. 2008;93:190–195.
   PubMed Web of Science ®Google Scholar
• Magiakou MA, Manousaki D, Papadaki M, et al. The efficacy and safety of gonadotropin-releasing hormone analog treatment in childhood and adolescence: a single center, long-term follow-up study. J Clin Endocrinol Metab. 2010;95:109–117.
   PubMed Web of Science ®Google Scholar
• Carel J-C, Roger M, Ispas S, et al. Final height after long-term treatment with triptorelin slow release for central precocious puberty: importance of statural growth after interruption of treatment. J Clin Endocrinol Metab. 1999;84:1973–1978.
   PubMed Web of Science ®Google Scholar
• Adan L, Chemaitilly W, Trivin C, et al. Factors predicting adult height in girls with central precocious puberty: implications for treatment. Clin Endocrinol. 2002;56:297–302.
   PubMed Web of Science ®Google Scholar
• Faienza MF, Brunetti G, Acquafredda A, et al. Metabolic outcomes, bone health, and risk of polycystic ovary syndrome in girls with idiopathic central precocious puberty treated with gonadotropin-releasing hormone analogues. Horm Res Paediatr. 2017;87:162–169.
   PubMed Web of Science ®Google Scholar
• Liang Y, Wei H, Li J, et al. Effect of GnRHa 3.75 mg subcutaneously every 6 weeks on adult height in girls with idiopathic central precocious puberty. J Pediatr Endocrinol Metab. 2015;28:839–846.
   PubMed Web of Science ®Google Scholar
• Kauli R, Galatzer A, Kornreich L, et al. Final height of girls with central precocious puberty, untreated versus treated with cyproterone acetate or GnRH analogue. Comparative study with re-evaluation predictions by Bayley-Pinneau method. Horm Res. 1997;47:54–61.
   PubMed Web of Science ®Google Scholar
• Bayley N, Pinneau SR. Tables for predicting adult height from skeletal age: revised for use with the Greulich-Pyle hand standards. J Pediatr. 1952;40:423–441.
   PubMed Web of Science ®Google Scholar
• Kletter GB, Kelch RP. Clinical review 60: effects of gonadotropin-releasing hormone analog therapy on adult stature in precocious puberty. J Clin Endocrinol Metab. 1994;79:331–334.
   PubMed Web of Science ®Google Scholar
• Arrigo T, Cisternino M, Galluzzi F, et al. Analysis of the factors affecting auxological response to GnRH agonist treatment and final height outcome in girls with idiopathic central precocious puberty. Eur J Endocrinol. 1999;141:140–144.
   PubMed Web of Science ®Google Scholar
• Bajpai A, Sharma J, Kabra M, et al. Long-acting GnRH analogue triptorelin therapy in central isosexual precocious puberty. Indian Pediatr. 2002;39:633–639.
   PubMedGoogle Scholar
• Lazar L, Padoa A, Phillip M. Growth pattern and final height after cessation of gonadotropin-suppressive therapy in girls with central sexual precocity. J Clin Endocrinol Metab. 2007;92:3483–3489.
   PubMed Web of Science ®Google Scholar
• Rizzo V, De Sanctis V, Corrias A, et al. Factors influencing final/near-final height in 12 boys with central precocious puberty treated with gonadotrophin-releasing hormone agonists. Italian Study Group Physiopathology Puberty J Pediatr Endocrinol Metab. 2000;13(Suppl 1):781–786.
   PubMedGoogle Scholar
• Galluzzi F, Salti R, Bindi G, et al. Adult height comparison between boys and girls with precocious puberty after long-term gonadotrophin-releasing hormone analogue therapy. Acta Paediatr. 1998;87:521–527.
   PubMed Web of Science ®Google Scholar
• Lazar L, Pertzelan A, Weintrob N, et al. Sexual precocity in boys: accelerated versus slowly progressive puberty gonadotropin-suppressive therapy and final height. J Clin Endocrinol Metab. 2001;86:4127–4132.
   PubMed Web of Science ®Google Scholar
• Mul D, Bertelloni S, Carel JC, et al. Effect of gonadotropin-releasing hormone agonist treatment in boys with central precocious puberty: final height results. Horm Res. 2002;58:1–7.
   PubMedGoogle Scholar
• Oostdijk W, Rikken B, Schreuder S, et al. Final height in central precocious puberty after long term treatment with a slow release GnRH agonist. Arch Dis Child. 1996;75:292–297.
   PubMed Web of Science ®Google Scholar
• Trivin C, Couto-Silva AC, Sainte-Rose C, et al. Presentation and evolution of organic central precocious puberty according to the type of CNS lesion. Clin Endocrinol (Oxf). 2006;65:239–245.
   PubMed Web of Science ®Google Scholar
• Carel JC. Blumberg J.Seymour C, et al. Triptorelin 3-month CPP study group three-month sustained-release triptorelin (11.25 mg) treatment central precocious puberty Eur J Endocrinol. 2006;154:119–124.
   PubMed Web of Science ®Google Scholar
• MartÍnez-Aguayo A, Hernández MI, Beas F, et al. Treatment of central precocious puberty with triptorelin 11.25 mg depot formulation. J Pediatr Endocrinol Metab. 2006;19:963–970.
   PubMed Web of Science ®Google Scholar
• Chiocca E, Dati E, Baroncelli GI, et al. Central precocious puberty: treatment with triptorelin 11.25 mg. ScientificWorldJournal. 2012;2012:583751.
   PubMedGoogle Scholar
• Bertelloni S, Massart F, Einaudi S, et al. Central precocious puberty: adult height in girls treated with quarterly or monthly gonadotropin-releasing hormone analog triptorelin. Horm Res Paediatr. 2015;84:396–400.
   PubMed Web of Science ®Google Scholar
• Mul D, Oostdijk W, Drop SL. Early puberty in girls. Best Pract Res Clin Endocrinol Metab. 2002;16:153–163.
   PubMed Web of Science ®Google Scholar
• Bertelloni S, Massart F, Miccoli M, et al. Adult height after spontaneous pubertal growth or GnRH analog treatment in girls with early puberty: a meta-analysis. Eur J Pediatr. 2017;176:697–704.
   PubMed Web of Science ®Google Scholar
• Llop-Viñolas D, Vizmanos B, Closa Monasterolo R, et al.. Onset puberty at eight years age girls determines specific tempo puberty but does not affect adult height Acta Paediatr. 2004;93:874–879.
   PubMed Web of Science ®Google Scholar
• Tonini G, Lazzerini M. Side effects of GnRH analogue treatment in childhood. J Pediatr Endocrinol Metab. 2000;13(Suppl 1):795–803.
   PubMedGoogle Scholar
• Yeshaya A, Kauschansky A, Orvieto R, et al. Prolonged vaginal bleeding during central precocious puberty therapy with a long-acting gonadotropin-releasing hormone agonist. Acta Obstet Gynecol Scand. 1998;77:327–329.
   PubMed Web of Science ®Google Scholar
• Miller BS, Shukla AR. Sterile abscess formation in response to two separate branded long-acting gonadotropin-releasing hormone agonists. Clin Ther. 2010;32:1749–1751.
   PubMed Web of Science ®Google Scholar
• Lee JW, Kim HJ, Choe YM, et al. Significant adverse reactions to long-acting gonadotropin-releasing hormone agonists for the treatment of central precocious puberty and early onset puberty. Ann Pediatr Endocrinol Metab. 2014;19:135–140.
   PubMedGoogle Scholar
• Ökdemir D, Hatipoğlu N, Akar HH, et al. A patient developing anaphylaxis and sensitivity to two different GnRH analogues and a review of literature. J Pediatr Endocrinol Metab. 2015;28:923–925.
   PubMed Web of Science ®Google Scholar
• Akın O, Yavuz ST, Hacıhamdioğlu B, et al. Anaphylaxis to gonadorelin acetate in a girl with central precocious puberty. J Pediatr Endocrinol Metab. 2015;28:1387–1389.
   PubMed Web of Science ®Google Scholar
• Heger S, Müller M, Ranke M, et al. Long-term GnRH agonist treatment for female central precocious puberty does not impair reproductive function. Mol Cell Endocrinol. 2006;254-255:217–220.
   PubMed Web of Science ®Google Scholar
• Lazar L, Meyerovitch J, de Vries L, et al. Treated and untreated women with idiopathic precocious puberty: long-term follow-up and reproductive outcome between the third and fifth decades. Clin Endocrinol (Oxf). 2014;80:570–576.
   PubMed Web of Science ®Google Scholar
• Murram D, Dewhurst J, Grant DB. Precocious puberty: a follow up study. Arch Dis Child. 1984;59:77–78.
   PubMed Web of Science ®Google Scholar
• Bertelloni S, Mul D. Treatment of central precocious puberty by GnRH analogs: long-term outcome in men. Asian J Androl. 2008;10:525–534.
   PubMed Web of Science ®Google Scholar
• Feuillan PP, Jones JV, Barnes KM, et al. Boys with precocious puberty due to hypothalamic hamartoma: reproductive axis after discontinuation of gonadotropin-releasing hormone analog therapy. J Clin Endocrinol Metab. 2000;85:4036–4038.
   PubMed Web of Science ®Google Scholar
• Ramos CO, Latronico AC, Cukier P, et al. Long-term outcomes of patients with central precocious puberty due to hypothalamic hamartoma after GnRH analog treatment: anthropometric, metabolic and reproductive aspects. Neuroendocrinology. 2018;106:203–210.
   PubMed Web of Science ®Google Scholar
• Antoniazzi F, Bertoldo F, Zamboni G, et al. Bone mineral metabolism in girls with precocious puberty during gonadotrophin-releasing hormone agonist treatment. Eur J Endocrinol. 1995;133:412–417.
   PubMed Web of Science ®Google Scholar
• Iannetta R, Melo AS, Iannetta O, et al. Use of a gonadotropin-releasing hormone analog to treat idiopathic central precocious puberty is not associated with changes in bone structure in postmenarchal adolescents. J Pediatr Adolesc Gynecol. 2015;28:304–308.
   PubMed Web of Science ®Google Scholar
• Massart F, Federico G, Harrell JC, et al. Growth outcome during GnRH agonist treatments for slowly progressive central precocious puberty. Neuroendocrinology. 2009;90:307–314.
   PubMed Web of Science ®Google Scholar
• Lanes R, Soros A, Jakubowicz S. Accelerated versus slowly progressive forms of puberty in girls with precocious and early puberty. gonadotropin suppressive effect final height obtained with two different analogs J Pediatr Endocrinol Metab. 2004;17:759–766.
   PubMed Web of Science ®Google Scholar
• Gillis D, Karavani G, Hirsch HJ, et al. Time to menarche and final height after histrelin implant treatment for central precocious puberty. J Pediatr. 2013;163:532–536.
   PubMed Web of Science ®Google Scholar
• Leger J, Reynaud R, Czernichow P. Do all girls with apparent idiopathic precocious puberty require gonadotropin-releasing hormone agonist treatment? J Pediatr. 2000;137:819–825.
   PubMed Web of Science ®Google Scholar
• Palmert MR, Malin HV, Boepple PA. Unsustained or slowly progressive puberty in young girls: initial presentation and long-term follow-up of 20 untreated patients. J Clin Endocrinol Metab. 1999;84:415–423.
   PubMed Web of Science ®Google Scholar
• Lazar L, Pertzelan A, Weintrob N, et al. Sexual precocity in boys: accelerated versus slowly progressive puberty gonadotropin-suppressive therapy and final height. J Clin Endocrinol Metab. 2001;86:4127–4132.
   PubMed Web of Science ®Google Scholar